Kronox Lab Sciences Board Approves Q2 & H1 FY26 Standalone Unaudited Financial Results
Kronox Lab Sciences approved Q2 and H1 FY26 standalone unaudited financial results. Q2 PAT rose to ₹874.29 lakhs and H1 PAT to ₹1306.69 lakhs, showing positive growth.
The announcement of quarterly and half-yearly financial results is a regular event, but the positive growth in PAT and EPS could have a moderate positive impact on investor sentiment and stock performance.
The company reported an increase in Profit after Tax (PAT) and Earnings per Share (EPS) for both the quarter and half-year ended 30th September 2025 compared to the previous year's corresponding periods, indicating improved financial performance.
Kronox Lab Sciences Limited announced the outcome of its Board Meeting held on Tuesday, 11th November 2025. * The Board of Directors considered and approved the Standalone Unaudited Financial Results for the quarter and half-year ended 30th September 2025. * The Independent Auditors’ Limited Review Report on Financial Results was also taken on record. * For the quarter ended 30th September 2025: * Revenue from Operations stood at ₹2553.32 lakhs. * Profit after Tax was ₹874.29 lakhs. * Earnings per equity share (Basic & Diluted) was ₹1.82. * For the half-year ended 30th September 2025: * Revenue from Operations was ₹4981.97 lakhs. * Profit after Tax was ₹1306.69 lakhs. * Earnings per equity share (Basic & Diluted) was ₹3.54. * The Board meeting commenced at 3:30 p.m. and concluded at 4:45 p.m. * The company's only reportable segment is the manufacturing of High Purity Specialty Fine Chemicals. * Kronox Lab Sciences had given a Final Dividend of 5% for the FY 2024-25 in September 2025.
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.